FINWIRES · TerminalLIVE
FINWIRES

調査速報:フリーポート・マクモラン第1四半期:好調な株価はグラスバーグ株の回復の遅れによって相殺される

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。FCXは、第1四半期の調整後EPSが前年同期の0.24ドルに対し0.57ドルとなり、市場予想を0.10ドル上回りました。売上高は前年同期比9%増の62億3000万ドルで、市場予想を2億7700万ドル上回りました。銅価格が30%上昇して1ポンドあたり5.78ドル、金価格が59%上昇して1オンスあたり4,889ドルと、商品価格が堅調に推移したことが、インドネシアの生産能力低下による銅の24%減、金の66%減を相殺しました。生産面での課題にもかかわらず、営業利益は64%増の21億3700万ドルとなり、商品価格の上昇に対する大きなレバレッジ効果を示しました。ただし、この効果は価格が下落する局面では逆方向に働くことに留意する必要があります。 FCXは、グラスバーグ鉱山の再稼働の遅れにより、2026年の生産ガイダンスを銅31億ポンド(3億ポンド減)、金65万オンスに下方修正した。改訂後のタイムラインでは、2026年下半期に65%、2027年半ばまでに80%、2027年末までにフル稼働を目指しており、これは以前の予想から大幅な遅れとなる。浸出技術は第1四半期に5400万ポンドの生産に貢献し、2026年の目標である3億ポンドと2030年までの目標である8億ポンドを支えている一方、地理的分散によりキャッシュフローの安定性が維持されている。

Related Articles

Treasury

Scotiabank Previews This Week's February and Preliminary March GDP for Canada

Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.

$$CXY
Australia

Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing

Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%

$VICR
Australia

BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says

BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%

$BMRN$FOLD